Front. Pharmacol.
Frontiers in Pharmacology
Front. Pharmacol.
1663-9812
Frontiers Media S.A.
1519505
10.3389/fphar.2024.1519505
Pharmacology
Correction
Corrigendum: The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China
Li et al.
10.3389/fphar.2024.1519505
Li
Lu
1
Yang
Shilei
1
Fang
Fengqi
2
Tian
Li
1
He
Ying
1
Li
Jia
2
*
Chen
Yanwei
1
*
Dong
Deshi
1
*
1
Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian, China
2
Department of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian, China
Edited and reviewed by: Bernd Rosenkranz, Fundisa African Academy of Medicines Development, South Africa
*Correspondence: Jia Li, lijia_211@hotmail.com; Yanwei Chen, chenyanweile@163.com; Deshi Dong, dongdeshi@dmu.edu.cn
11
11
2024
2024
15
1519505
30
10
2024
01
11
2024
Copyright © 2024 Li, Yang, Fang, Tian, He, Li, Chen and Dong.
2024
Li, Yang, Fang, Tian, He, Li, Chen and Dong
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A Corrigendum on The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China by Li L, Yang S, Fang F, Tian L, He Y, Li J, Chen Y and Dong D (2024). Front. Pharmacol. 15:1382120. doi: 10.3389/fphar.2024.1382120
HER-2-positive metastatic breast cancer
network meta-analysis
cost-effectiveness analysis
pyrotinib plus capecitabine
T-DM1
T-DXd
section-at-acceptance
Drugs Outcomes Research and Policies
In the published article, there was an error. T-DXd was indicated for comparison with PC strategies instead of T-DM1.
A correction has been made to the Abstract, Findings. This sentence previously stated:
“The PC strategies are considered more cost-effective than T-DXd when the WTP threshold is set at $36,058.06 per QALY.”
The corrected sentence appears below:
“The PC strategies are considered more cost-effective than T-DM1 when the WTP threshold is set at $36,058.06 per QALY.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.